#USA #South San Francisco #CAR-T Technology #Oncology Therapy #Link Cell Therapies

Link Cell Therapies Begins Clinical Trials for LNK001

Link Cell Therapies, a pioneering oncology cell therapy company based in South San Francisco, is making significant strides in cancer treatment with the initiation of clinical dosing for its first therapy, LNK001. This groundbreaking therapy employs a novel approach known as logic-gating technology to target cancers more effectively while minimizing damage to healthy tissues. This article delves into the details of their recent advancements, leadership changes, and financial developments.

Initiating Clinical Trials

LNK001 is designed as an AND-gated CAR-T therapy, targeting two specific antigens—CAIX and ENPP3—both of which are significantly raised in advanced clear cell renal cell carcinoma (RCC). The clinical trial for LNK001 is being conducted at the renowned MD Anderson Cancer Center, marking an important step in the development of treatments for this aggressive form of cancer.

Traditionally, therapies targeting the CAIX antigen have faced issues due to on-target, off-tumor toxicity, particularly affecting biliary tissues. However, by utilizing an AND-gating mechanism that requires the co-expression of both CAIX and ENPP3, LNK001 aims to maintain the anti-tumor potential while sparing healthy cells from exposure. This innovative strategy represents a significant advancement in the pursuit of effective cancer therapies that do not compromise patient safety.

Expansion of Leadership Team

In addition to the progression of LNK001, Link Cell Therapies has announced key additions to its executive leadership team to guide the next phases of development and commercialization. Jie D'Elia, Ph.D., has been appointed as the new Chief Executive Officer. Dr. D'Elia brings with her an extensive portfolio from her previous role at SystImmune, Inc., and her significant contributions at Bristol Myers Squibb, where she was instrumental in forging strategic partnerships that advanced multiple therapeutic areas.

Brian Slingerland, co-founder of Link and a key figure in its establishment, will now assume the role of Executive Chair. Slingerland's experience in the biotech sector is considerable—his former company, Stemcentrx, was recognized for groundbreaking advancements in antibody-drug conjugates (ADCs) and achieved a historic acquisition by AbbVie.

Friedrich Graf Finckenstein, M.D., joins the team as Chief Medical Officer. His impressive background includes contributions to significant drug developments in oncology, including the approval of AMTAGVI® for solid tumors.

Financial Boost to Enhance Development

Link has also expanded its Series A financing from $60 million to $90 million. The additional funds will facilitate the clinical and preclinical development of its innovative CAR-T programs. This expansion is backed by several notable investors, including Johnson & Johnson, BMS, and other venture capital partners, highlighting the confidence in Link’s approach and future potential.

The increased funding will also enable Link to advance its second solid tumor program targeting colorectal cancer, aiming to initiate first-in-human trials in 2027. This program will utilize a new pair of target antigens that are abundant in colorectal tumors but absent from healthy tissues.

Looking Ahead

Dr. D'Elia expressed optimism regarding the implications of Link's unique logic-gating strategy, suggesting it holds the potential to expand the application of CAR-T treatments in solid tumors significantly. This could pave the way for CAR-T therapies achieving the same lasting responses in solid cancers as seen in hematologic malignancies.

The leadership at Link is optimistic and unwavering in their commitment to translating their innovative scientific advancements into reliable therapies that can fundamentally change the landscape of cancer treatment.

In conclusion, Link Cell Therapies is carving a path towards innovative cancer treatments through its unique logic-gating technology. As the clinical trials for LNK001 progress and the company continues to expand its leadership and financing, it stands at the forefront of a new era in oncology care. Investors and healthcare professionals alike are keenly watching what comes next for this ambitious company with a promising vision for the future of cancer treatment.